Loading
A phase 3 trial of TQB2930 and Trastuzumab in HER2-positive breast cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer is a phase 3 interventional study registered as NCT07047365 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 416 participants planned, started 2025-07-25 and due to reach its primary completion in 2028-06. Interventions recorded: TQB2930+ chemotherapy and Trastuzumab+ chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TQB2930, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares TQB2930, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/